Role of hormone therapy in the management of menopause

Obstetrics and Gynecology

Volumn 115, Issue 4, 2010, Pages 839-855

  Shifren, Jan L ^a   Schiff, Isaac ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLIMACTERIUM; COGNITION; COLORECTAL CANCER; DEPRESSION; ENDOMETRIUM CANCER; ESTROGEN THERAPY; GYNECOLOGIC DISEASE; HEALTH HAZARD; HEART DISEASE; HORMONAL THERAPY; HOT FLUSH; HUMAN; INCONTINENCE; ISCHEMIC HEART DISEASE; LIVER DISEASE; LOW DRUG DOSE; MENOPAUSE; MOOD; MORTALITY; NIGHT SWEAT; OSTEOPOROSIS; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SHORT COURSE THERAPY; THROMBOEMBOLISM; TREATMENT CONTRAINDICATION; UROGENITAL ATROPHY; VASOMOTOR DISORDER;

AGED; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE;

EID: 77949890853     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181d41191     Document Type: Review

References (93)

1. Wilson RA. Feminine forever. New York (NY): M. Evans; 1966.
2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooper-berg C, Stefanick ML, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333
3. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477
4. Schiff I, Regestein Q, Tulchinsky D, Ryan KJ. Effects of estrogens on sleep and psychological state of hypogonadal women. JAMA 1979;242:2405-2407
5. Woods N, Mitchell E. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives. Am J Med 2005;118:14S-24S.
6. Oldenhave A, Jaszmann LJ, Haspels AA, Everaerd WT. Impact of climacteric on well-being: a survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol 1993;168: 772-780
7. Gold EB, Sternfeld B, KelseyJL, Brown C, Mouton C, Reame N, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol 2000;152:463-473
8. Whiteman MK, Staropoli CA, Langenberg PW, McCarter RJ, Kjerulff KH, Flaws JA. Smoking, body mass, and hot flashes in midlife women. Obstet Gynecol 2003;101:264-272
9. Freedman RR, Subramanian M. Effects of symptomatic status and the menstrual cycle on hot flash-related thermoregulatory parameters. Menopause 2005;12:156-159
10. Maclennan A, BroadbentJ, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. The Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No. CD002978. DOI: 10.1002/ 14651858.CD002978.pub2.
11. Utian WH, Shoupe D, Bachmann G, PinkertonJV, PickarJH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065-1079
12. Schiff I, Tulchinsky D, Cramer D, Ryan KJ. Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA 1980;244:1443-1445
13. Bachmann GA, Schaefers M, Uddin A, Utian WH. Lowest effective transdermal 17/3-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2007;110:771-779
14. Notelovitz M, LenihanJP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 17/3-estradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000;95:726-731
15. Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR, Nikcevich DA, et al. Phase III comparison of depo-medroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J Clin Oncol 2006;24:1409-1414
16. Goodwin JW, Green SJ, Moinpour CM, Bearden JD III, Giguere JK, Jiang CS, et al. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626. J Clin Oncol 2008; 26:1650-1656
17. Kronenberg F, Barnard RM. Modulation of menopausal hot flashes by ambient temperature. J Therm Biol 1992;17:43-49
18. Newton KM, Buist DS, Keenan NL, Anderson LA, LaCroix AZ. Use of alternative therapies for menopause symptoms: results of a population-based survey. Obstet Gynecol 2002; 100:18-25.
19. Avis NE, Legault C, Coeytaux RR, Pian-Smith M, ShifrenJL, Chen W, et al. A randomized, controlled pilot study of acupuncture treatment for menopausal hot flashes. Menopause 2008;15:1070-1078
20. Krebs EE, Ensrud KE, MacDonald R, Wilt TJ. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol 2004;104:824-836
21. Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, GuiltinanJ. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2006;145: 869-879
22. Barton DL, Loprinzi CL, Quella SK, Sloan JA, Veeder MH, Egner JR, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998;16: 495-500.
23. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-2063
24. Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. Gabap-entin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003;101: 337-345
25. Soares CN, Joffe H, Rubens R, Caron J, Roth T, Cohen L. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol 2006;108:1402-1410
26. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007;14:357-369
27. Suckling J, Kennedy R, Lethaby A, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. The Cochrane Database of Systematic Reviews 2006, Issue 4. Art No. CD001500. DOI: 10.1002/14651858.CD001500.pub2.
28. Handa VL, Bachus KE, Johnston WW, Robboy SJ, Hammond CB. Vaginal administration of low-dose conjugated estrogens: systemic absorption and effects on the endometrium. Obstet Gynecol 1994;84:215-218
29. Henriksson L, Stjernquist M, Boquist L, Cedergren I, Selinus I. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of uro-genital aging. Am J Obstet Gynecol 1996;174:85-92.
30. Weisberg E, Ayton R, Darling G, Farrell E, Murkies A, O'Neill S, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005; 8:83-92.
31. Dew JE, Wren BG, Eden JA. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study. Climacteric 2002;5: 151-155
32. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006;17: 584-587
33. Hendrix SL, Cochrane BB, Nygaard IE, Handa VL, Barnabei VM, Iglesia C, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA 2005;293:935-948
34. Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 1999;180:1072-1079
35. Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178-180
36. National Osteoporosis Foundation. Disease statistics. Fast facts. 2004. Available at: www.nof.org. Retrieved January 22, 2010.
37. World Health Organization. Assessment of osteoporosis at the primary health care level: summary report of a WHO Scientific Group. Geneva: World Health Organization; 2007.
38. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. 2nd ed. Washington, DC: National Osteoporosis Foundation; 2008.
39. Watts N, Ettinger B, LeBoff M. Perspective: FRAX facts. J Bone Min Res 2009;24:975-979
40. Tosteson AN, Melton LJ III, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, et al; National Osteoporosis Foundation Guide Committee. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporosis Int 2008;19: 437-447
41. Cauley JA, ZmudaJM, Ensrud KE, Bauer DC, Ettinger B; Study of Osteoporotic Fractures Research Group. Timing of estrogen replacement therapy for optimal osteoporosis prevention. J Clin Endocrinol Metab 2001;86:5700-5705
42. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, et al; Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density. JAMA 2003;290:1729-1738
43. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17/3-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 2003;290:1042-1048
44. Ettinger B, Ensrud KE, Wallace R, Johnson KC, Cummings SR, Yankov V, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004;104:443-451
45. Yates J, Barrett-Connor E, Barlas S, Chen Y-T, Miller P, Siris E. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol 2004;104:440-446
46. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-2082
47. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-1352
48. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822
49. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al; Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350:1189-1199
50. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nick-elsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-645
51. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al; Raloxifene Use for the Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-137
52. Neer RM, Arnaud CD, ZanchettaJR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N EnglJ Med 2001;344:1434-1441
53. Cummings SR, San MartinJ, McClung MR, Siris ES, Eastell R, Reid IR, et al; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-765
54. Stampfer MJ, Colditz GA, Willet WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756-762
55. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmeno-pausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995;273:199-208.
56. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med 1991;115:455-456
57. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmeno-pausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712
58. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613
59. Clarke S, Kelleher J, Lloyd-Jones H, Slack M, Schofield P. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT Atherosclerosis Study. Br J Obstet Gynaecol 2002;109: 1056-1062
60. Harman S, Brinton E, Cedars M, Lobo R, Manson JE, Merriam GR, et al. KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric 2005;8:3-12.
61. Manson JE, Bassuk SS. Invited commentary: hormone therapy and risk of coronary heart disease\why renew the focus on the early years of menopause? Am J Epidemiol 2007;166:511-517
62. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, et al; WHI and WHI-CACS Investigators. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007; 356:2591-2602
63. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, et al; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestins\the ESTHER study. Circulation 2007;115:840-845
64. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403.
65. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000;343:16-22.
66. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64.
67. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-1059
68. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-491
69. Chen WY, Manson JE, Hankinson SE, Rosner B, Holmes MD, Willett WC, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006;166:1027-1032
70. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427
71. Holmberg L, Anderson H; HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer\is it safe?), a randomised comparison: trial stopped. Lancet 2004;363:453-455
72. Vogel VG, Costantino JP, Wickerham DL, Cronon WM, Cecchini RS, Atkins JN, et al; National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741
73. Anderson GG, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, et al; Women's Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003;290:1739-1748
74. Chapman J, DiSaia P, Osann K, Roth P, Gillotte D, Berman M. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996;175:1195.
75. Mørch LS, Løkkegaard E, Andreasen AH, Krüger-Kjaer S, Lidegaard O. Hormone therapy and ovarian cancer. JAMA 2009;302:298-305.
76. American College of Obstetricians and Gynecologists. Hormone therapy. Obstet Gynecol 2004;104(suppl 4):S1-129.
77. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998;279:688-695
78. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al; WHIMS Investigators. Estrogen plus proges-tin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study\a randomized controlled trial. JAMA 2003;289:2651-2662
79. Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, et al; Women's Health Initiative Memory Study. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2959-2968
80. Avis NE, Crawford S, Stellato R, Longcope C. Longitudinal study of hormone levels and depression among women tran-sitioning through menopause. Climacteric 2001;4:243-249
81. Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perim-enopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001;58:529-534
82. Zweifel JE, O'Brien WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psycho-neuroendocrinology 1997;22:189-212.
83. Utian WH, Archer DF, Bachmann GA, Gallagher C, Grod-stein F, Heiman JR, et al; North American Menopause Society. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15:584-602.
84. Archer DF, Dorin M, Lewis V, Schneider DL, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001;75:1080-1087
85. Ettinger B, Selby J, Citron JT, Vangessel A, Ettinger VM, Hendrickson MR. Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 1994;83:693-700.
86. Varila E, Wahlström T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001;76:969-973
87. Shifren JL, Desindes S, McIlwain M, Doros G, Mazer NA. A randomized, open label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women. Menopause 2007;14:985-994
88. Grady D, Ettinger B, Tosteson AN, Pressman A, Macer JL. Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstet Gynecol 2003;102:1233-1239
89. Haskell SG, Bean-Mayberry B, Gordon K. Discontinuing postmenopausal hormone therapy: an observational study of tapering versus quitting cold turkey: is there a difference in recurrence of menopausal symptoms? Menopause 2009; 16:494-499
90. Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses' Health Study. Obstet Gynecol 2009;113:1027-1037
91. Rivera CM, Grossardt BR, Rhodes DJ, Brown RD Jr, Roger VL, Melton LJ III, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 2009;16:15-23.
92. Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossa-rdt BR, de Andrade M, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorec-tomy before menopause. Neurology 2007;69:1074-1083
93. Martin KA, Manson JE. Approach to the patient with menopausal symptoms. J Clin Endocrinol Metab 2008; 93:4567-4575